Comparison of the Effect Site Concentration of Remifentanil for Preventing Cough During Emergence Between Male and Female Patients With Thyroidectomy
Status
Conditions
Treatments
Details and patient eligibility
About
The clinical studies demonstrate more powerful analgesic effect among female to both μ- and κ-opioid agonist (Fillingim et al. 2004). The antitussive effect of opioid is mediated predominantly by μ-, κ-opioid receptors (Kamei J. 1996). Therefore, the investigators hypothesized that there are sex differences in the antitussive responses to opioid.
It has been reported that target-controlled infusion (TCI) of remifentanil can reduce cough against endotracheal tube during emergence from general anesthesia. Some studies, reporting the EC50 and EC95 of remifentanil in effect-site TCI for preventing cough during emergence in different sex and surgeries (B. Lee et al. 2009, E.M.Choi et al. 2012), showed differences in EC50 and EC95.
The purpose of this study was to find out EC50 and EC95 of remifentanil in effect-site TCI for preventing cough during emergence in each sex and to evaluate whether there were sex differences in EC50 and EC95 of remifentanil in effect-site TCI or not.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- aged 20-46
- ASA classification I~II
- patients undergoing thyroidectomy
Exclusion criteria
- patient who has signs of a difficult airway
- patient who has smoking history
- patient who has upper respiratory infection or sore throat in the previous two weeks
- patient who has hypertension, DM
- female patients who were pregnant, breast-feeding or menopausal
Trial design
Primary purpose
Allocation
Interventional model
Masking
46 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal